| Identification | Back Directory | [Name]
N-[(4-chloro-2-methylphenyl)methyl]-1-(4-chlorophenyl)-N-[(5-nitrothiophen-2-yl)methyl]methanamine | [CAS]
1438071-12-5 | [Synonyms]
GSK-2945
GSK-2945
(GSK2945 )
GSK 2945
DISCONTINUED. Please see G797405
2-Thiophenemethanamine, N-[(4-chloro-2-methylphenyl)methyl]-N-[(4-chlorophenyl)methyl]-5-nitro-
N-[(4-chloro-2-methylphenyl)methyl]-1-(4-chlorophenyl)-N-[(5-nitrothiophen-2-yl)methyl]methanamine | [Molecular Formula]
C20H18Cl2N2O2S | [MDL Number]
MFCD32204617 | [MOL File]
1438071-12-5.mol | [Molecular Weight]
421.34 |
| Chemical Properties | Back Directory | [Boiling point ]
525.0±45.0 °C(Predicted) | [density ]
1.363±0.06 g/cm3(Predicted) | [solubility ]
Acetonitrile (Slightly), DMSO (Slightly, Heated), Methanol (Slightly, Sonicated) | [form ]
Solid | [pka]
5.23±0.50(Predicted) | [color ]
Off-White to Light Beige | [Stability:]
Hygroscopic |
| Hazard Information | Back Directory | [Uses]
GSK 2945 is an antagonist with high specificity for REV-ERBα, Nuclear heme receptor reverse erythroblastosis virus, which is known to regulate circadian rhythm and more specifically, regulation of cholesterol 7α-hydroxylase (CYP7A1) and bile acid synthesis. | [in vivo]
GSK2945 (0-10 mg/kg; intraperitoneal injection; twice every day; for 7 days; male C57BL/6 mice) treatment increases hepatic mouse cholesterol 7α-hydroxylase (Cyp7a1) level and lowers plasma cholesterol in wild-type mice[1]. | Animal Model: | Male C57BL/6 mice (8-10 weeks of age)[1] | | Dosage: |
0 mg/kg or 10 mg/kg | | Administration: | Intraperitoneal injection; twice every day; for 7 days | | Result: | Increased hepatic mouse cholesterol 7α-hydroxylase (Cyp7a1) level and lowered plasma cholesterol in wild-type mice.
|
|
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|